Indication: For the treatment of hypertension.
Pharmacology: Irbesartan, an angiotensin II receptor antagonist similar to losartan and valsartan, is used alone or with hydrochlorothiazide to treat hypertension
Mechanism Of Action: Irbesartan antagonizes angiotensin II, the primary vasoactive hormone of the renin-angiotensin system, at the AT1 receptor subtype. As angiotensin II is vasoconstrictor which stimulates aldosterone secretion by the adrenal gland, blockage of its effects results in a decrease in systemic vascular resistance.
Drug Category: Antihypertensive Agents; Angiotensin II Receptor Antagonists; ATC:C09CA04
Brand Names/Synonyms: Avalide; Avapro; CHEMBANK1635; Irbesarran; Irbesartan; Irbesartan [Usan:Inn]; Lrbesartan
Dosage Forms: Oral tablets
Absorption: 60-80%
Interactions:
DrugBank: Interactions for Irbesartan
Interactions for Irbesartan:
No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in
interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.
In vitro studies show significant inhibition of the formation of oxidized irbesartan
metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.
However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were
negligible. Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent
upon cytochrome P450 isozymes 1A1, 1A2,2A6,2B6,2D6,2E1,or 3A4.
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or
digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or
pharmacokinetics of digoxin. The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine
or hydrochlorothiazide.
Chemical IUPAC Name: 3-butyl-2-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-2,4-diazaspiro[4.4]non-3-en-1-one
Chemical Formula: C25H28N6O
Half Life: 11-15 hours
Drug Type: Approved Drug
# Accession No: APRD00413
CAS Registry Number: 138402-11-6
